MY KOLKATA EDUGRAPH
ADVERTISEMENT
regular-article-logo Saturday, 27 April 2024

DGCA issues guidelines on transportation of vaccine packed in dry ice

'Flight crew should be trained on risks of method'

Our Bureau, Agencies New Delhi Published 08.01.21, 07:38 PM
India’s drugs regulator has approved Oxford Covid-19 vaccine Covishield, being manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country.

India’s drugs regulator has approved Oxford Covid-19 vaccine Covishield, being manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country. Representational file picture

Aviation regulator DGCA on Friday issued guidelines to all aircraft operators who plan to transport Covid-19 vaccines packed in dry ice to various parts of the country.

“If vaccines packed in dry ice are being transported in the passenger cabin of an aircraft, then the flight crew should be properly trained on the hazards and risks of its transportation,” it noted.

ADVERTISEMENT

“Dry ice transforms into carbon dioxide gas at temperatures higher than -78 degrees Celsius under normal atmospheric pressure and, therefore, it is classified as “dangerous goods” by the International Civil Aviation Organization (ICAO),” it said.

The Directorate General of Civil Aviation (DGCA) said, “Adequate number of carbon dioxide detectors should be available in the cabin. Such detectors should be located at locations for timely and reliable detection of a dangerous concentration of carbon dioxide.”

“All operators while engaging in the transportation of Covid-19 vaccines packed with dry ice shall establish the maximum quantity of dry ice that can be loaded in a given cargo hold or the main deck (passenger cabin) when a passenger version is deployed for all cargo operations,” it said.

The country is preparing for the roll-out of Covid-19 vaccines and the second nationwide mock drill on the drive was conducted on Friday.

India’s drugs regulator has approved Oxford Covid-19 vaccine Covishield, being manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country.

Follow us on:
ADVERTISEMENT